What changed: Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)
Every dated change on the records linked to Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result1Milestone6This record1
September 2026 · 1
2022 · 1
2019 · 1
2013 · 2
- 2013Trial resultLCH-IIILCH-III reported
12 vs 6 months of vinblastine-prednisone: 5-year reactivation 37% vs 54% in risk-organ-negative disease; methotrexate added no benefit.
- 2013MilestoneLCH-IIILCH-III: twelve months of therapy halves reactivation; methotrexate adds nothing
A milestone in how this cancer is treated.